Table 1.
Clinical background of cases during the state of emergency due to COVID-19.
| Total (n = 748) | Analyzed cases | During the state of emergency |
|---|---|---|
| Male (%) | 748 | 424 (57%) |
| Age (years-old) | 748 |
67.3 ± 12.3 (range, 22–97) |
| Current smoke | 520 | 31 (6%) |
| Hypertensin | 748 | 714 (95%) |
| Diabetes mellitus | 748 | 423 (57%) |
| Dyslipidemia | 610 | 544 (89%) |
| Chronic kidney disease | 610 | 336 (55%) |
| Cardiovascular disease | 610 | 104 (17%) |
| Cerebrovascular disease | 610 | 40 (7%) |
| BMI | 519 | 24.0 ± 3.5 |
| BW (kg) | 715 | 63.9 ± 12.8 |
| Office SBP/DBP (mmHg) | 748 |
138.6 ± 18.6/ 79.0 ± 12.2 |
| Office MAP (mmHg) | 748 | 99.0 ± 12.5 |
| Pulse rate | 520 | 79.2 ± 13.2 |
| Home SBP/DBP (mmHg) | 546 |
126.8 ± 10.3/ 75.3 ± 9.1 |
| Home MAP (mmHg) | 546 | 92.5 ± 8.2 |
| eGFR (mL/min/1.73 m2) | 565 | 66.9 ± 17.8 |
| HbA1c(mmol/mol (%)) | 546 |
48.1 ± 10.1 (6.5 ± 0.9) |
| Urine albumin-to creatinine ratio (mg/gCr) | 391 | 9.5 [5.4, 26.1] |
| Urine protein (g/gCr) | 79 | 0.16 [0.05, 0.39] |
| Estimated Sodium intake (g/day) | 503 | 8.8 [7.2, 10.4] |
| NT proBNP | 178 | 91.0 [40.5, 193.0] |
| Current medications were analyzed in 610 cases | ||
| Antihypertensive agents | ||
| ARB | 308 (51%) | |
| ACEI | 40 (7%) | |
| Ca channel blocker | 297 (49%) | |
| β blocker | 84 (14%) | |
| Thiazide | 22 (4%) | |
| Mineralocorticoid receptor blocker | 45 (7%) | |
| Loop diuretic | 9 (2%) | |
| hypoglycemic agents | ||
| DPP4 inhibitor | 150 (25%) | |
| Metformin | 97 (16%) | |
| SGLT2 inhibitor | 68 (11%) | |
| Insulin | 51 (8%) | |
| Sulphonyl urea | 64 (11%) | |
| GLP1 receptor agonist | 20 (3%) | |
| Pioglitazone | 34 (6%) | |
| `αGlucosidase inhibitor | 70 (12%) | |
| Glinide | 32 (5%) | |
| Others | ||
| Statin | 439 (72%) | |
| Ezetimibe | 92 (15%) | |
| Fibrate | 12 (2%) | |
| Antiplatelet | 126 (21%) | |
| EPA | 34 (6%) | |
| Anticoagulant | 22 (4%) | |
Data shown are mean ± standard deviation, median [lower quartile, upper quartile], or numbers (%).
ACEI angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, COVID-19 corona virus disease 2019, BMI body mass index, BW body weight, DBP diastolic blood pressure, DPP4 dipeptidyl peptidase-4, EPA eicosapentaenoic acid, eGFR estimated glomerular filtration rate, GLP1 glucagon-like peptide 1, HbA1c hemoglobin A1c, MAP mean arterial pressure, NT proBNP N-terminal pro-brain natriuretic peptide, SBP systolic blood pressure, SGLT2 sodium-glucose co-transporter 2.